1. Home
  2. LEGN vs RYAN Comparison

LEGN vs RYAN Comparison

Compare LEGN & RYAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • RYAN
  • Stock Information
  • Founded
  • LEGN 2014
  • RYAN 2010
  • Country
  • LEGN United States
  • RYAN United States
  • Employees
  • LEGN N/A
  • RYAN N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • RYAN Specialty Insurers
  • Sector
  • LEGN Health Care
  • RYAN Finance
  • Exchange
  • LEGN Nasdaq
  • RYAN Nasdaq
  • Market Cap
  • LEGN 9.1B
  • RYAN 7.8B
  • IPO Year
  • LEGN 2020
  • RYAN 2021
  • Fundamental
  • Price
  • LEGN $38.19
  • RYAN $70.94
  • Analyst Decision
  • LEGN Strong Buy
  • RYAN Buy
  • Analyst Count
  • LEGN 13
  • RYAN 11
  • Target Price
  • LEGN $81.46
  • RYAN $70.33
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • RYAN 808.9K
  • Earning Date
  • LEGN 11-12-2024
  • RYAN 10-30-2024
  • Dividend Yield
  • LEGN N/A
  • RYAN 0.62%
  • EPS Growth
  • LEGN N/A
  • RYAN 53.91
  • EPS
  • LEGN N/A
  • RYAN 0.77
  • Revenue
  • LEGN $520,183,000.00
  • RYAN $2,324,982,000.00
  • Revenue This Year
  • LEGN $110.04
  • RYAN $26.22
  • Revenue Next Year
  • LEGN $77.16
  • RYAN $20.37
  • P/E Ratio
  • LEGN N/A
  • RYAN $91.61
  • Revenue Growth
  • LEGN 122.96
  • RYAN 20.14
  • 52 Week Low
  • LEGN $38.02
  • RYAN $41.49
  • 52 Week High
  • LEGN $70.13
  • RYAN $73.10
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 29.40
  • RYAN 56.09
  • Support Level
  • LEGN $38.94
  • RYAN $71.16
  • Resistance Level
  • LEGN $41.87
  • RYAN $72.40
  • Average True Range (ATR)
  • LEGN 2.20
  • RYAN 2.03
  • MACD
  • LEGN -0.30
  • RYAN 0.14
  • Stochastic Oscillator
  • LEGN 1.74
  • RYAN 83.32

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About RYAN Ryan Specialty Holdings Inc.

Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.

Share on Social Networks: